CardiAMP's Promise | Explore BioCardia's innovative cell therapy for heart failure, showing potential in reducing cardiac events and improving quality of life for patients |
FDA Backing | Learn how the FDA's protocol amendment expands patient eligibility for CardiAMP HF II trial, potentially accelerating development and improving outcomes |
Financial Boost | Delve into the impact of CMS reimbursement approval on BioCardia's trial costs and development timeline, enhancing the company's financial outlook |
Market Opportunity | Analysts set price targets ranging from $4 to $25, reflecting the potential of BioCardia's therapy in the growing cardiovascular treatment market |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Metrics to compare | BCDA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCDAPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.1x | −2.3x | −0.6x | |
PEG Ratio | −0.02 | −0.06 | 0.00 | |
Price/Book | −4.8x | 1.8x | 2.6x | |
Price / LTM Sales | 21.9x | 29.6x | 3.3x | |
Upside (Analyst Target) | - | 134.9% | 49.0% | |
Fair Value Upside | Unlock | 17.7% | 7.7% | Unlock |